🔎 Trials Near Me

Home › Pathologic Constriction › NCT05561127

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

RecruitingPhase 3

Who can join

Ages 22 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

1. Age ≥ 22
2. Diagnosis of symptomatic benign bowel stricture with at least 2 previous dilations.
3. Willing and able to complete protocol required follow up
4. Willing and able to provide written informed consent
5. Stricture length ≤ 5 cm

Exclusion Criteria:

1. Female subjects who are pregnant or breastfeeding or plan to get pregnant in next 12 months
2. Contraindication to endoscopy, anesthesia, or deep sedation.
3. Suspicion of malignant bowel stricture NOTE: Biopsy should be taken for every stricture during the initial endoscopy, however endoscopic balloon dilation may proceed without awaiting results if suspicion for malignancy is low in the opinion of the investigator.
4. Benign stricture due to extrinsic compression
5. Stricture is not amenable to standard balloon dilation (e.g. severe angulation, unable to pass guidewire, etc.)
6. Stricture complicated with abscess, fistula, perforation, leakage or varices
7. Stricture segment has moderate to severe active inflammation at the time of treatment. Moderate to severe inflammation is defined as any one of; ulcers \>0.5cm in diameter, ulcerated surface \>10%, affected (inflamed) surface \>50%, marked erythema, absent vascular pattern, significant friability, or erosions
8. Multiple clinically significant strictures unable to be treated with a single balloon (i.e. total segment length must be ≤5cm) NOTE: Clinically significant strictures include those that are unable to be passed by the endoscope.
9. Received steroid injections into target stricture in the last 8 weeks
10. Stricture is not able to be dilated to ≥15mm in small bowel or ≥18mm in large bowel
11. Diagnosis of metastatic cancer of any type that is not considered in remission or non-metastatic cancer that may require radiation treatment in the pelvic region (e.g. prostate cancer)
12. Suspected perforation of gastrointestinal tract
13. Active systemic infection
14. Allergy to paclitaxel
15. Severe coagulation disorders or current use of anticoagulant or antiplatelet medication that cannot be safely managed per relevant societal guidelines
16. Chronic systemic steroid use (defined as greater than 10 mg/day) for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use
17. Condition requiring treatment in urgent setting
18. Life expectancy of less than 24 months
19. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety, such as recent myocardial infarction, severe pulmonary disease, bleeding diathesis, large thoracic aneurysm, pharyngeal or cervical deformity, etc.
20. Current participation in another pre-market drug or medical device clinical study unless in long term follow-up

About the study

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

What is being tested

Sponsor: GIE Medical · Participants: 171 · Started: Nov 1, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT05561127

Locations in the U.S.

ArizonaHonor Health, Scottsdale
CaliforniaUniversity of California, Irvine, Irvine
Gastro Care Institute, Lancaster
Cedars Sinai, Los Angeles
San Diego Gastroenterology, San Diego
ColoradoUniversity of Colorado Anschutz, Aurora
FloridaUniversity of Florida, Gainesville
Borland-Groover, Jacksonville
Research Associates of South Florida, Miami
Hillcrest Medical Research, Orange City (Not yet recruiting)
Orlando Health, Orlando
Orlando Health, Orlando
GeorgiaGastroenterology Associates of Central Georgia, LLC, Macon
IllinoisRush University, Chicago
KansasKansas Gastroenterology, LLC, Wichita
KentuckyUniversity of Louisville, Louisville
LouisianaTandem Clinical Research, Marrero
MassachusettsBrigham and Women's Hospital, Boston
MissouriWashington University, St Louis
New JerseyRutgers University, Piscataway
New YorkLenox Hill Hospital, New York
New York Presbyterian Hospital- Columbia University Medical Center, New York
North CarolinaUniversity of North Carolina, Chapel Hill
PennsylvaniaEinstein Medical Center, Philadelphia
Thomas Jefferson University, Philadelphia
University of Pennsylvania, Philadelphia
Allegheny Health Network, Pittsburgh
TennesseeVanderbilt University Medical Center, Nashville
TexasBaylor St. Luke's Medical Center, Houston
UtahThe University of Utah, Salt Lake City
WashingtonSwedish Medical Center, Seattle
Virginia Mason, Seattle
West VirginiaWest Virginia University, Morgantown

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.